BRITISH COLUMBIA, Canada, Aug. 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX VENTURE: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, today announced the addition of a new product designated DXLr120 (CD20). This is the third product added to the growing InNexus pipeline and was developed using new recombinant methods to produce a DXL(TM) anti CD20 antibody. InNexus' first and second products were developed with chemical methods to impart DXL(TM) into the development of new antibodies and the latest product represents a significant patent expansion for the company.
InNexus Chief Scientific Officer, Dr. Thomas Kindt, said, "Within the past two years, InNexus has moved rapidly to accelerate preclinical development of multiple candidates. Use of recombinant methods to develop DXLr120 with our patented DXL(TM) technology demonstrates the expertise of our team and the opportunity we have to create multiple therapeutic and diagnostic antibodies."
DXLr120 significantly improves antibodies binding to CD20, the target for Non Hodgkin's Lymphoma and Rheumatoid Arthritis and joins InNexus' well-studied DXL625 (CD20). DXL625, developed with chemical methods, also significantly improves the binding of antibodies to CD20 and increases potency using both in vitro and in vivo studies. Preliminary data for DXLr120 already reveals properties akin to those shown for DXL625. Plans are underway to subject DXLr120 to the full battery of tests for potency, in vivo efficacy and safety used for DXL625.
The company will present at IBC's 13th Annual World Congress Drug Discovery & Development of Innovative Therapeutics (DDT) Conference in Boston at the World Trade Center Boston. The InNexus presentation will be within the Main Conference (amphitheater) beginning at 9:40 AM (ET) on Wednesday, August 6th. Jeff Morhet, Chief Executive Officer and Dr. Thomas Kindt, Chief Scientific Officer will present an in-depth presentation of a Case Study of InNexus' preclinical candidate DXL625 (CD20): A New Platform for Augmenting Antibody Therapeutics for Cancer.
About Recombinant Antibodies
Antibodies are protein molecules produced by our immune system. The shape of an antibody is often described in a Y shape and one of their critical roles is to recognize and attack foreign bacteria and viruses. Antibodies come in numerous forms and each type can recognize unique antigen (targets). Each arm of the antibody (upper portion of the Y) has unique molecular structure (keys) that combine with the targets. Attachment of many antibodies to an object with these targets ultimately causes its destruction. Recombinant technologies have seen an explosion in use as manufacturing procedures have streamlined with shortened time frames and the final product often has a greater quality than that of products from non-recombinant methods.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
|SOURCE InNexus Biotechnology Inc.|
Copyright©2008 PR Newswire.
All rights reserved